HPV vaccines | NITAG RESOURCE CENTER

Overview

In September 2022, SAGE endorsed an off-label single-dose schedule for human papillomavirus (HPV) vaccination, concluding that a single dose provides durable protection against HPV infections comparable to the two-dose regimen. Following this recommendation, countries have implemented or are considering changes in schedule that can contribute to the simplification of the vaccine delivery and result in significant budgetary savings. The focus of this compendium sheet is to summarize the evidence in support of the single dose schedule of HPV vaccines.

Looking for a comparing key characteristics of different available HPV vaccines?

Compare vaccine type

General indicators for HPV vaccines

Number of new cases per year (last 3-5 years)

Proportion of the population affected by the disease or infected with the antigen

Serogroup or serotype distribution (for serogroup- or serotype-specific vaccines)

Number of deaths from the disease per year

Case Fatality ratio (number of deaths / number of new cases, in %)

Outbreak, epidemic or pandemic risk

Contribution of the vaccine to achievement of the national, regional or global disease goals

Serogroup or serotype coverage by vaccines considered (for serogroup- or serotype-specific vaccines)

Efficacy and effectiveness estimates (e.g. against infection, disease, hospitalization, death), including in different populations

Duration of protection and waning of immunity in general and risk groups

Type, including severity, consequences and frequency of short- and long-term adverse events following vaccination

Perception of the target population on the risk of disease

Acceptability of the vaccine and of vaccination against the disease

Estimated financial cost of materials per vaccine dose (syringes, needles, safety box) (in USD)

Estimated vaccine financial cost per dose (in USD)

Estimated financial cost per person vaccinated (in USD)

Cost-effectiveness ratio

Is there a Gavi programme to support the introduction of this vaccine? If a Gavi programme is available, what support is available to countries?

Available vaccines, licensing status, prequalification status, presentation, formulation, dosage and route of administration

Number of doses and timing of administrations

Cold chain volume required per vaccine dose (in cm3)

Disclaimer

Data are mostly derived from recent WHO and NITAG official publications, peer reviewed papers, other publicly available sources and institutional publications. Not all data are the result of a systematic review with an assessment of the certainty of evidence; in addition, the evidence does not cover every aspect of the respective indicator. Users are encouraged to review the data sources in detail and consider any additional data that may be available, including regional and local data.